?
Optimal patient selection**: Which patients would benefit most from P2X7 antagonism?
active
open question
Created: 2026-04-25T20:27:32
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-3d06b7e0-f36e-4b74-bec0-9c
Open Question
open
Wiki: therapeutics-p2x7-receptor-antagonists-neurodegeneration
Optimal patient selection**: Which patients would benefit most from P2X7 antagonism?
Importance Elo
1500
Field Rank
Rank #968 in therapeutics
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page therapeutics-p2x7-receptor-antagonists-neurodegeneration
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
No cross-references found yet. Evidence matching runs daily.
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
▸Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:27:32.760693'} |
| field_tag | therapeutics |
| source_id | therapeutics-p2x7-receptor-antagonists-neurodegeneration |
| sub_field | p2x7-receptor-antagonists-neurodegeneration |
| source_kind | wiki |
| question_hash | 1dc0ae14635306251e405614173cfbac613a6f3b4858c368a91830b36fd5da31 |
| question_text | Optimal patient selection**: Which patients would benefit most from P2X7 antagonism? |
| importance_elo | 1500 |
| _schema_version | 1 |
| evidence_summary | Extracted from wiki page therapeutics-p2x7-receptor-antagonists-neurodegeneration |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.